Literature DB >> 21041709

Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis.

David Palma1, Otto Visser, Frank J Lagerwaard, Jose Belderbos, Ben J Slotman, Suresh Senan.   

Abstract

PURPOSE: Stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) is associated with high local control rates. The impact of introducing SBRT in patients 75 years of age or older was studied using a population-based cancer registry.
METHODS: The Amsterdam Cancer Registry was assessed in three eras: 1999 to 2001 (period A, pre-SBRT); 2002 to 2004 (period B, some availability of SBRT), and 2005 to 2007 (period C, full access to SBRT). χ(2), Kaplan-Meier, and Cox regression were used to compare treatment patterns and overall survival (OS) in three treatment groups: surgery, radiotherapy (RT), or neither.
RESULTS: A total of 875 elderly patients were diagnosed with stage I NSCLC in the study period. Median follow-up was 54 months. Primary treatment was surgery in 299 patients (34%), RT in 299 patients (34%), and neither in 277 patients (32%). RT use increased between periods A and C (26% v 42%, P < .01), corresponding to a decrease in untreated patients. The percentage of RT patients undergoing SBRT in periods B and C was 23% and 55%, respectively. Median survival for all patients increased from 16 months in period A to 21 months in period C (log-rank P < .01; hazard ratio [HR] = 0.65; 95% CI, 0.54 to 0.80). The improvement in OS was confined to RT patients (HR = 0.70; 95% CI, 0.49 to 0.99), whereas no significant survival improvements were seen in the other groups.
CONCLUSION: SBRT introduction was associated with a 16% absolute increase in RT use, a decline in the proportion of untreated elderly patients, and an improvement in OS.

Entities:  

Mesh:

Year:  2010        PMID: 21041709     DOI: 10.1200/JCO.2010.30.0731

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  118 in total

1.  What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer?

Authors:  Matthias Guckenberger
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

2.  [Evidence for the use of modern irradiation techniques for non-small cell lung cancer: unnecessary, inadequate, insufficient or too late?].

Authors:  M Guckenberger
Journal:  Strahlenther Onkol       Date:  2012-03       Impact factor: 3.621

3.  Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.

Authors:  Charles B Simone; Jay F Dorsey
Journal:  Ann Transl Med       Date:  2015-08

Review 4.  New techniques for assessing response after hypofractionated radiotherapy for lung cancer.

Authors:  Sarah A Mattonen; Kitty Huang; Aaron D Ward; Suresh Senan; David A Palma
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

5.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

6.  Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.

Authors:  Daniel H Schanne; Ursula Nestle; Michael Allgäuer; Nicolaus Andratschke; Steffen Appold; Ute Dieckmann; Iris Ernst; Ute Ganswindt; Anca L Grosu; Richard Holy; Michael Molls; Meinhard Nevinny-Stickel; Sabine Semrau; Florian Sterzing; Andrea Wittig; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-08-27       Impact factor: 3.621

7.  Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.

Authors:  Jacob Y Shin; Ja Kyoung Yoon; Gaurav Marwaha
Journal:  Lung       Date:  2018-03-17       Impact factor: 2.584

8.  Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.

Authors:  Janaki A Deepak; Xinyi Ng; Josephine Feliciano; Li Mao; Amy J Davidoff
Journal:  Ann Am Thorac Soc       Date:  2015-05

9.  A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer.

Authors:  Christopher Cao; Daniel Wang; Caroline Chung; David Tian; Andreas Rimner; James Huang; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2018-09-15       Impact factor: 5.209

10.  Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes.

Authors:  Sashendra Senthi; Cornelis J A Haasbeek; Frank J Lagerwaard; Wilko F Verbakel; Patricia F de Haan; Ben J Slotman; Suresh Senan
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.